| 04.24.18 | Zerhouni out as Sanofi R&D head as Roche exec takes the helm, following a string of Big Pharma research moves

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

6 jahre vor

Html
Text

To view this email as a web page, click here

This week's sponsor is Premier Research.
	Opportunity Knocks: Seizing the Promise of Orphan Drugs Orphan drug developers enjoy more favorable regulatory conditions today than ever. Read our white paper for tips on maximizing this opportunity. Premier Research. It's what we do. Best.

Today's Rundown

Sanofi hires ex-Roche executive John Reed to replace retiring Elias Zerhouni as R&D chief Restless R&D executives, and a few FDA staffers, on the move to rival pharmas Adcomm backs lower dose of Lilly, Incyte's baricitinib but not higher [Sponsored] Can the SEC step in to support small businesses if Congress stalls? FDA slaps partial hold on Epizyme’s lead drug; analysts say ‘don’t panic’ Eli Lilly unveils galcanezumab migraine analysis as FDA decisions near Alnylam builds out case for patisiran, showing sharp drop in hospitalization, mortality Revolution Medicines tees up for oncology IND with $56M series B Shire-hunting Takeda notches R&D collaboration with Nektar, pair to combo I-O drugs Cedilla Therapeutics launches with $56M to target protein degradation in cancer Urovant poaches Allergan's key urology executive Cornelia Haag-Molkenteller

Featured Story

Sanofi hires ex-Roche executive John Reed to replace retiring Elias Zerhouni as R&D chief

Tuesday, April 24, 2018

Sanofi is changing its head of global R&D. Elias Zerhouni, M.D., is to retire from the position at the end of June, leaving former Roche research leader John Reed, M.D., Ph.D., to take charge of Sanofi’s pipeline.

This week's sponsor is Deloitte.

Restless R&D executives, and a few FDA staffers, on the move to rival pharmas

Tuesday, April 24, 2018

The last few weeks have seen major R&D moves from big pharma companies including Sanofi, AstraZeneca, Roche, Gilead, Novartis, Amgen and GlaxoSmithKline.

Adcomm backs lower dose of Lilly, Incyte's baricitinib but not higher

Monday, April 23, 2018

The expert panel voted 10-5 in favor of the 2-mg dose but flipped those numbers to vote 10-5 against the 4-mg dose.

[Sponsored] Can the SEC step in to support small businesses if Congress stalls?

Monday, April 23, 2018

Congress is debating whether to include small businesses in the Senate’s bank bill. But the SEC has an opportunity to take action on SOX 404(b) on its own.

FDA slaps partial hold on Epizyme’s lead drug; analysts say ‘don’t panic’

Tuesday, April 24, 2018

Shares in Epizyme slipped in premarket trading today after the company announced a suspension of patient recruitment in a trial of its lead cancer drug after a patient developed a secondary lymphoma, but analysts at Jefferies are expecting the stock to bounce back.

Eli Lilly unveils galcanezumab migraine analysis as FDA decisions near

Tuesday, April 24, 2018

Eli Lilly presented a post hoc analysis of its monthly migraine therapy galcanezumab, one of a new class of targeted preventive drugs, as it looks to show the drug's effectiveness after the failure of other treatments.

Alnylam builds out case for patisiran, showing sharp drop in hospitalization, mortality

Tuesday, April 24, 2018

Alnylam has presented a fresh take on its phase 3 patisiran data as it builds out its case ahead of an anticipated landmark approval. The new angle comes from an exploratory post hoc analysis which linked the RNAi therapy to a 50% drop in all-cause hospitalization and mortality over placebo.

Revolution Medicines tees up for oncology IND with $56M series B

Tuesday, April 24, 2018

The capital will push Revolution's lead program, a SHP2 inhibitor, into the clinic. Since its launch in 2014, the Bay Area biotech has narrowed its focus to "frontier targets," or targets that have previously been considered undruggable.

Shire-hunting Takeda notches R&D collaboration with Nektar, pair to combo I-O drugs

Tuesday, April 24, 2018

Takeda, with apparently near infinitely deep pockets for M&A and collaborations, has struck a deal: not to buy Shire, as yet, but rather with Nektar, as the two eye new trials of their respective immuno-oncology assets.

Cedilla Therapeutics launches with $56M to target protein degradation in cancer

Tuesday, April 24, 2018

Cedilla is targeting processes that transition cancer-driving proteins from a stable state to a state susceptible to degradation.

Urovant poaches Allergan's key urology executive Cornelia Haag-Molkenteller

Tuesday, April 24, 2018

Urovant Sciences is bringing on Allergan’s Cornelia Haag-Molkenteller as its chief medical officer and establishing a new U.S. headquarters in California. The move comes shortly after launching a phase 3 trial for vibegron, its sole drug candidate, in overactive bladder.

This week's sponsor is PharmaCord.

Enrollment Showcase

Online Graduate Programs Designed for Your Career

Resources

[Whitepaper] Risk-based Approach to Change Management of GxP Systems

Sponsored by: Veeva Systems

Learn how to reduce change management burden, keep systems current, and maintain compliance by applying a risk-based approach to change management of GxP systems.

[Whitepaper] Compliance Certificate and Training for Life Sciences Professionals

[Whitepaper] MSL Outlook: What is the Future of Field Medical Affairs?

Sponsored by: Veeva Systems

Learn how leading companies, from the world’s top pharma to emerging biotechs, are empowering their medical affairs teams.

[Whitepaper] Leveraging Scientific Insights for Better Healthcare Engagement

Sponsored by: Veeva Systems

To deliver value to key opinion leaders, medical affairs needs to tailor their engagement with deeper analytics and insights.

[Whitepaper] The Future of Life Sciences Events Management

Sponsored by: Veeva Systems

Explore a new model for events management, and learn how to deliver more value.

[Whitepaper] Not Like Everyone Else: Unique Challenges for Small Biopharma Companies

[Whitepaper] For Fixed-Dose Combination Manufacturing, Confidence Matters

[Whitepaper] 2018 Life Sciences Trends

[Video] So Many Choices: What’s the Right Biomanufacturing Strategy for Me?

Presented by: Patheon, part of Thermo Fisher Scientific

Patheon's Stephen Lam reviews the formidable challenges and decisions facing biopharma manufacturing executives. Watch as he shares unique insights and perspectives and demonstrates how there is really no one-size-fits-all solution in biomanufacturing, regardless of company size.

[Meeting] AACR Annual Meeting 2018

Presented by: Charles River

How do you get your oncology therapy to the clinic? The path isn’t always clear. In vitro, ex vivo, xenograft, syngeneic, PDX, humanized models, immunology considerations, safety regulations – which do you need to plan for and when?

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Presented by: Covance

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.